UCLA researchers identify two drugs that may target ALS inflammation

For decades, ALS has dismantled human bodies without offering medicine a clear point of intervention in its most common form. Now, researchers at UCLA have found that two existing drugs — one already trusted in the treatment of multiple sclerosis — can quiet the immune system's assault on motor neurons in laboratory conditions, suggesting that the disease's autoimmune dimension may finally be addressable. The discovery does not promise a cure, but it opens a door that has long appeared sealed: the possibility of redirecting tools already in hand toward a disease that has resisted them.